The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma
In: European Journal of Cancer vol. 30 no. 4, pp. 457-459, 1994
academicJournal
Zugriff:
In a retrospective study, we calculated the treatment costs of 26 patients, who received either high dose melphalan combined with granulocyte colony-stimulating factor (G-CSF; filgrastim)(n=7) or without G-CSF (n=11) or alternatively, peripheral blood progenitor cell reinfusion (PBPC) mobilised by G-CSF following high dose melphalan. In comparison with the control group, a shortening of the pancytopenic period and platelet recovery was noticed in the PBPC group. This resulted in a reduction in hospital costs, diagnostics, laboratory services, total parenteral nutrition and transfusions. The average costs per treatment in the PBPC group amounted to about US$ 179 08 as compared to US$ 32 223 in the control group, implying a cost reduction of 44% when changing to PBPC reinfusion.
Titel: |
The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma
|
---|---|
Autor/in / Beteiligte Person: | Uyl-de Groot, C.A. (Carin) ; Ossenkoppele, G.J. (Gert) ; Riet, A.A.P.M. (A. A P M) van ; Rutten, F.F.H. (Frans) |
Link: | |
Zeitschrift: | European Journal of Cancer vol. 30 no. 4, pp. 457-459, 1994 |
Veröffentlichung: | 1994 |
Medientyp: | academicJournal |
DOI: | 10.1016/0959-8049(94)90418-9 |
Schlagwort: |
|
Sonstiges: |
|